Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 May;55(5):469–476. doi: 10.1038/bjc.1987.96

The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.

M I Walton, N M Bleehen, P Workman
PMCID: PMC2001726  PMID: 3606940

Abstract

We have investigated the effects of 50 min whole-body hyperthermia (WBH; 15 min equilibration followed by 41 degrees C for 35 min) on the toxicity and pharmacokinetics of the radiosensitizer Ro 03-8799 in mice. WBH markedly reduced Ro 03-8799 LD50/7d from 779 to 259 micrograms g-1 (P less than 0.001). Pharmacokinetics were studied at 175 micrograms g-1 (approximately 0.6 WBH LD50/7d) with and without heat and 437 micrograms g-1 (approximately 0.6 control LD50/7d) without heat. WBH increased Ro 03-8799 plasma concentrations and prolonged its elimination t1/2 by 26% (P less than 0.01). Total plasma area under the curve (AUC0-infinity) was increased by 22%, but was still less than 50% of the unheated high-dose value. Ro 03-8799 concentrated 300-400% in tumour and brain relative to plasma. Absolute tumour and brain levels were unaltered by WBH, giving reduced tissue/plasma ratios. WBH greatly inhibited glomerular filtration (51Cr EDTA clearance) during heating, contributing to the increased plasma Ro 03-8799 concentrations. WBH increased peak plasma concentrations of the Ro 03-8799 N-oxide metabolite Ro 31-0313 by 61% and the beta-phase AUC of i.v. administered Ro 31-0313 by 36%. Since Ro 31-0313 levels were increased to a greater extent after Ro 03-8799 and WBH than Ro 31-0313 and WBH, WBH must both increase metabolite production and decrease its plasma clearance. WBH had no effect on Ro 31-0313 tumour concentrations or its exclusion from brain. These complex effects of WBH on Ro 03-8799 pharmacokinetics may contribute to the enhanced toxicity, possibly through hyperthermia-stimulated bioreductive drug activation, but do not wholly explain it.

Full text

PDF
469

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Flockhart I. R., Smithen C. E., Stratford I. J., Wardman P., Watts M. E. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976 Jul;67(1):9–20. [PubMed] [Google Scholar]
  2. Allen J. G., Dische S., Lenox-Smith I., Malcolm S. L., Saunders M. I. The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans. Eur J Clin Pharmacol. 1984;27(4):483–489. doi: 10.1007/BF00549599. [DOI] [PubMed] [Google Scholar]
  3. Bickel M. H. The pharmacology and biochemistry of N-oxides. Pharmacol Rev. 1969 Dec;21(4):325–355. [PubMed] [Google Scholar]
  4. Bleehen N. M., Honess D. J., Morgan J. E. Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer. 1977 Mar;35(3):299–306. doi: 10.1038/bjc.1977.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown J. M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980 Apr;82(1):171–190. [PubMed] [Google Scholar]
  6. Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed] [Google Scholar]
  7. Collins F. G., Skibba J. L. Altered hepatic functions and microsomal activity in perfused rat liver by hyperthermia combined with alkylating agents. Cancer Biochem Biophys. 1983;6(4):205–211. [PubMed] [Google Scholar]
  8. Conroy P. J., McNeill T. H., Passalacqua W., Merritt J., Reich K. R., Walker S. Nitroimidazole neurotoxicity: are mouse studies predictive? Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):799–803. [PubMed] [Google Scholar]
  9. Daly J. M., Wang Y. M., Kapelanski D., Frazier O. H. Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. J Surg Res. 1984 Nov;37(5):343–347. doi: 10.1016/0022-4804(84)90198-7. [DOI] [PubMed] [Google Scholar]
  10. Dennis M. F., Stratford M. R., Wardman P., Watts M. E. Cellular uptake of misonidazole and analogues with acidic or basic functions. Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jun;47(6):629–643. doi: 10.1080/09553008514550871. [DOI] [PubMed] [Google Scholar]
  11. Dvorchik B. H., Vessell E. S. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther. 1978 Jun;23(6):617–623. doi: 10.1002/cpt1978236617. [DOI] [PubMed] [Google Scholar]
  12. George K. C., Hirst D. G., McNally N. J. Effect of hyperthermia on cytotoxicity of the radiosensitizer Ro-07-0582 in a solid mouse tumour. Br J Cancer. 1977 Mar;35(3):372–375. doi: 10.1038/bjc.1977.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gomer C. J., Johnson R. J. Relationship between misonidazole toxicity and core temperature in C3H mice. Radiat Res. 1979 May;78(2):329–333. [PubMed] [Google Scholar]
  14. Honess D. J., Bleehen N. M. Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain. Br J Cancer. 1982 Aug;46(2):236–248. doi: 10.1038/bjc.1982.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Honess D. J., Donaldson J., Workman P., Bleehen N. M. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. Br J Cancer. 1985 Jan;51(1):77–84. doi: 10.1038/bjc.1985.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Honess D. J., Workman P., Morgan J. E., Bleehen N. M. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse. Br J Cancer. 1980 Apr;41(4):529–540. doi: 10.1038/bjc.1980.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Macy D. W., Macy C. A., Scott R. J., Gillette E. L., Speer J. F. Physiological studies of whole-body hyperthermia of dogs. Cancer Res. 1985 Jun;45(6):2769–2773. [PubMed] [Google Scholar]
  18. Magin R. L., Cysyk R. L., Litterst C. L. Distribution of adriamycin in mice under conditions of local hyperthermia which improve systemic drug therapy. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):203–210. [PubMed] [Google Scholar]
  19. Malcolm S. L., Lee A., Groves J. K. High-performance liquid chromatographic analysis of the new hypoxic cell radiosensitiser, Ro 03-8799, in biological samples. J Chromatogr. 1983 Apr 8;273(2):327–333. doi: 10.1016/s0378-4347(00)80953-6. [DOI] [PubMed] [Google Scholar]
  20. Mimnaugh E. G., Waring R. W., Sikic B. I., Magin R. L., Drew R., Litterst C. L., Gram T. E., Guarino A. M. Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits. Cancer Res. 1978 May;38(5):1420–1425. [PubMed] [Google Scholar]
  21. Overgaard J. Effect of local hyperthermia on the acute toxicity of misonidazole in mice. Br J Cancer. 1979 Jan;39(1):96–98. doi: 10.1038/bjc.1979.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Overgaard J. Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue. Br J Cancer. 1980 Jan;41(1):10–21. doi: 10.1038/bjc.1980.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rauth A. M. Pharmacology and toxicology of sensitizers: mechanism studies. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1293–1300. doi: 10.1016/0360-3016(84)90335-3. [DOI] [PubMed] [Google Scholar]
  24. Roberts J. T., Bleehen N. M., Walton M. I., Workman P. A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol. 1986 Feb;59(698):107–116. doi: 10.1259/0007-1285-59-698-107. [DOI] [PubMed] [Google Scholar]
  25. SMITH J. H., ROBINSON S., PEARCY M. Renal responses to exercise, heat and dehydration. J Appl Physiol. 1952 Feb;4(8):659–665. doi: 10.1152/jappl.1952.4.8.659. [DOI] [PubMed] [Google Scholar]
  26. Saunders M. I., Anderson P. J., Bennett M. H., Dische S., Minchinton A., Stratford M. R., Tothill M. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1759–1763. doi: 10.1016/0360-3016(84)90544-3. [DOI] [PubMed] [Google Scholar]
  27. Stratford I. J., Adams G. E. Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro. Br J Cancer. 1977 Mar;35(3):307–313. doi: 10.1038/bjc.1977.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Twentyman P. R., Kallman R. F., Brown J. M. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1255–1260. doi: 10.1016/0360-3016(79)90649-7. [DOI] [PubMed] [Google Scholar]
  29. Walton M. I., Bleehen N. M., Workman P. The reversible N-oxidation of the nitroimidazole radiosensitizer Ro 03-8799. Biochem Pharmacol. 1985 Nov 1;34(21):3939–3940. doi: 10.1016/0006-2952(85)90448-4. [DOI] [PubMed] [Google Scholar]
  30. Watts M. E., Jones N. R. The effect of extracellular pH on radiosensitization by misonidazole and acidic or basic analogues. Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jun;47(6):645–653. doi: 10.1080/09553008514550881. [DOI] [PubMed] [Google Scholar]
  31. White R. A., Workman P. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer. 1980 Feb;41(2):268–276. doi: 10.1038/bjc.1980.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Williams M. V., Denekamp J., Minchinton A. I., Stratford M. R. In vivo assessment of basic 2-nitroimidazole radiosensitizers. Br J Cancer. 1982 Jul;46(1):127–137. doi: 10.1038/bjc.1982.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Workman P., Brown J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981;6(1):39–49. doi: 10.1007/BF00253009. [DOI] [PubMed] [Google Scholar]
  34. Workman P. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol. 1980;5(1):27–37. doi: 10.1007/BF00578559. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES